

At last, rapid analgesia with rapid recovery.

New

Trademarks


RAPIFEN

(alfentanil)

minute by minute control of short procedures.

Prescribing Information **Presentation** Clear, colourless, aqueous injection, containing 500µg/ml alfentanil hydrochloride, in 2ml ampoules. **Uses** Analgesic adjunct to anaesthesia in short operative procedures and outpatient surgery, requiring spontaneous respiration. Rapifent may also be administered to ventilated patients undergoing longer operative procedures (see data sheet). **Dosage (Spontaneous respiration in adults)** Initial: Up to 500µg (1ml). This should be given by slow i.v. injection over about 30 seconds. **Supplemental:** Up to 250µg (0.5ml) every 4-5 minutes or sooner if the patient exhibits signs of insufficient analgesia. Anticipation of surgical stimulation is helpful. **Contra-indications, warnings etc.** Contra-indications: Obstructive airways disease or respiratory depression if not ventilating. Administration with MAOIs or within two weeks of their discontinuation. Administration in labour or before clamping of the cord during Caesarean section. Warnings: May produce a transient fall in blood pressure. Doses in excess of 1000µg (2ml) will produce significant respiratory depression, usually of short duration. This can be reversed with naloxone (0.1-0.2mg i.m. or i.v.). Bradycardia may occur and can be antagonised by atropine. Muscular rigidity (morphine-like effect) may occur and can be helped by muscle relaxants. Concurrent administration with other narcotic or CNS-depressant drugs can be expected to be additive in effect. **Precautions** Reduce dosage in the elderly, in hypothyroidism and in chronic liver disease. **Side effects** Nausea, vomiting and dizziness have been reported. **Use in pregnancy** Safety in humans has not been established. Risk should be weighed against potential benefit. **Overdosage** Symptoms should be treated as indicated in the 'Warnings' section above. General supportive measures should also be employed. **Pharmaceutical precautions** Combinations with alkaline agents should be avoided. **Basis NHS cost** 2ml x 10 ampoules £7.43. **Product licence numbers** 024/1/00021. Further information available from the product licence holder, Schering-Plough UK Ltd, Chesham, HP5 1JL, Tel: 01494 921111. 

He doesn't care, we do...



Burglaries are on the increase. So is the cost of insuring. You, however, are in a more fortunate position than many people you know. You have your own professional insurance broker, the Medical Insurance Agency.

- * MIA offers very competitive insurance rates exclusively to doctors, dentists and nurses.
- * All distributed profits of the MIA are donated to Medical, Dental and health care charities. To date these have benefited by over £1,500,000.

*** MIA has a new HOME & CONTENTS insurance policy. Besides offering you the lowest possible premium, it also allows you to pay that premium in easy monthly instalments.**

With competitive premiums and easy payments, MIA's new policy makes it comparatively 'painless' to protect yourself adequately against the loss resulting from fire, other damage and theft. Burglars couldn't 'care less' how you feel about the loss of hard-earned possessions. But MIA is an integral part of the caring professions. That's why we have produced the easy-payment solution. Send for details. You know it makes sense.

Already insured?

You may be over-insured. You may well be paying a higher premium than you would with MIA. Let us work out a comparative quotation for you. Send for our questionnaire now, so that we can advise the correct value of your property.



MEDICAL INSURANCE AGENCY LIMITED

Over 75 years' professional insurance expertise.
Branches throughout the U.K.

To the Medical Insurance Agency Limited, FREEPOST,
B.M.A. House, Tavistock Square, London WC1H 9BR Telephone: 01-388 1301

I am a member of the medical profession and could therefore benefit from the New MIA 'Home & Contents' insurance.

Please send details. (No stamp is needed if you use the FREEPOST address.)

BLOCK LETTERS PLEASE

Name (Dr, Mr, Mrs, Miss) _____

Address _____

There is no substitute for success



Prescribing Information
Uses: Sensitive bacterial infections of the lower respiratory, urinary and genital tracts, sinusitis, otitis media, skin infections, septicaemia, typhoid and paratyphoid fevers, and other infections caused by sensitive organisms.

Dosage: *Septin Forte Tablets*: over 12 years, one twice daily. *Septin Tablets/Septin Dispersible Tablets*: over 12 years, two twice daily; children 6 to 12 years, one twice daily. *Septin Suspensions*: over 12 years, 10ml Adult twice daily; children 6 to 12 years, 10ml Paediatric twice daily; 6 months to 6 years, 5ml Paediatric twice daily; 6 weeks to 6 months, 2.5ml Paediatric twice daily.

Contra-indications: Septin is contra-indicated in patients with marked liver parenchymal damage, blood dyscrasias or severe renal insufficiency. Septin should not be given to patients hypersensitive to sulphonamides or co-trimoxazole; should not be given during pregnancy or to neonates.

Precautions: In cases of renal impairment a reduced dosage is indicated and an adequate urinary output should be maintained.

in urinary tract infections **Septin b.d.**

Trade Mark

Regular blood counts are necessary whenever long-term therapy is used. Caution is advised in patients with folate deficiency. Care should be taken when giving Septin to patients receiving oral anti-coagulants of the coumarin group, pyrimethamine, sulphonylureas, or phenytoin.

Warnings and Adverse Effects: Occasionally nausea, vomiting, diarrhoea, glossitis and skin rashes may occur with normal doses and, very rarely, haematological reactions.

Further information is available on request.

Wellcome Medical Division

The Wellcome Foundation Ltd, Crewe, Cheshire.

I. Gower, P.E. and Tasker, P.R.W. (1976), *Brit. Med. J.*, 1, 684. Double-blind comparison of Septin with cephalaxin in 93 women with acute UTI. After two weeks, 96% of Septin-treated patients were infection free, compared with 68% of cephalaxin-treated patients.


Presentations:

	Product Licence	Formulation	Basic NHS Cost
Septin Forte Tablets	PL 3/0121	160mg Trimethoprim BP 800mg Sulphamethoxazole BP	£1.90 for 10
Septin Tablets	PL 3/0109	80mg TMP 400mg SMX	£2.27 for 20
Septin Dispersible Tablets	PL 3/0099	80mg TMP 400mg SMX	£2.42 for 20
Septin	PL 3/5223	80mg SMX 400mg TMP in 5ml	£3.22 for 100ml
Adult Suspension		400mg TMP	
Septin	PL 3/5222	40mg TMP 200mg SMX in 5ml	£2.00 for 100ml
Paediatric Suspension		20mg TMP 100mg SMX	
Paediatric Tablets	PL 3/0108		£0.69 for 20



IN HYPERTENSION AND ANGINA

put it all together...



...in one tablet daily

TENORMIN
fits the profile of the ideal beta blocker
in hypertension and angina

Tenormin' Prescribing notes:

Presentation: 'Tenormin' tablets containing atenolol 100 mg are round, bi-convex, orange and film coated. **Uses:** Management of hypertension and angina pectoris. **Dosage:** Hypertension: One tablet daily. Angina: 100 mg daily in single or divided doses. **Contraindications:** Heart block. Co-administration with verapamil. **Precautions:** Untreated cardiac failure, bradycardia, renal failure, anaesthesia and pregnancy. Clonidine withdrawal. **Side Effects:** Coldness of extremities and muscular fatigue. Sleep disturbance rarely seen. Rashes and dry eyes have been reported with beta blockers—consider discontinuance if they occur. Cessation of therapy with beta blockers should be gradual. **Pack size and Basic NHS cost:** 'Tenormin' 28's £7.05. **Product Licence Number:** 'Tenormin' 0029/0122.

Full prescribing information is available on request to the Company



Stuart Pharmaceuticals Ltd
Carr House, Carrs Road
Cheadle, Cheshire SK8 2EG
'Tenormin' is a trademark.



AN

responds  rapidly to

NEW
brufen
600 Ibuprofen B.P.

fast, dependable relief of
post-operative pain
post-episiotomy pain
dental pain
dysmenorrhoea
non-articular rheumatism
soft-tissue injuries

Prescribing Information. **Presentation:** Light-magenta, film-coated tablets containing 600mg of Ibuprofen B.P. **Uses:** Rheumatoid arthritis (including Still's disease), ankylosing spondylitis, osteoarthritis and other non-rheumatoid arthropathies. Non-articular rheumatic conditions such as capsulitis, bursitis, tendinitis, tenosynovitis, low back pain, soft tissue injuries. As an analgesic in mild to moderate pain. **Dosage:** Adult: Brufen 600 is indicated three times daily (1800mg day) for acute conditions. Total daily dose should not exceed 2400mg. **Contra-indications:** Severe or active peptic ulceration. **Warnings:** Prescribe with caution in patients with asthma and those who have developed bronchospasm with other non-steroidal agents. Avoid, if possible, during pregnancy. **Side-effects:** Dyspepsia, gastrointestinal intolerance and bleeding, skin rashes. Less frequently, thrombocytopenia, rarely toxic amblyopia. **Basic N.H.S. Price:** Brufen 600 100 pack £8.55. **Product Licence No:** Brufen 600 PL0014 0264. Brufen is a registered Trademark



The Boots Company PLC Nottingham
Further information on Brufen 600 is available on request.

just one tablet three times daily

A WORLDWIDE DEMONSTRATION OF THE POWER OF SYNERGY

• Azlocillin is a ureido-penicillin with excellent bactericidal activity against most Gram-negative and Gram-positive aerobic and anaerobic organisms! •

• Of the 116 bacteremias there was a 60% response with azlocillin and amikacin, compared with a response rate of 31% for [cefotaxime/amikacin and ticarcillin/amikacin]. The differences are statistically significant.²

Results of a worldwide study by the EORTC* on 549 immunocompromised patients.

SECUROOPEN AZLOCILLIN

THE POWERFUL PARTNER FOR YOUR AMINOGLYCOSIDE

PRESCRIBING INFORMATION Presentation Vials containing 0.5g, 1.0g, 2.0g and 5.0g azlocillin as azlocillin monosodium. Infusion Pack containing 3 x 5.0g infusion vials. 3 x 50ml Water for Injection BP. 3 x Transfer needles. 3 x Hanging bags. Uses Azlocillin is a broad spectrum injectable penicillin indicated for the treatment of a wide range of bacterial infections. Dosage and administration In non life threatening infections 2.0g i.v. 8 hourly. In patients with renal insufficiency the dosage interval should be 12 hours. Children's dosage is based on 3 x 75mg/kg bodyweight daily. Treatment should be administered for at least 3 days after clinical symptoms have disappeared. Infusion Pack: See detailed instructions on Packaging Leaflet. Contra-indications A history of allergy to other penicillins and cephalosporins. Securoopen is inactivated by B-lactamases (penicillinases). As with all new drugs Securoopen should not be used during the first 3 months of pregnancy. Side-effects As for other injectable penicillins. Pharmaceutical precautions Store below 25°C. Solution should be prepared immediately prior to administration by shaking with a suitable volume of Water for injections until dissolved; unused solution should be discarded. Legal Category POM. Basic NHS cost £2.48 per g (ex 5.0g vial). Product Licence Numbers PL0010/0075 Water for Injections BP: PL1502/0003.

Further information is available from: Bayer UK Limited, Pharmaceutical Division, Bayer House, Strawberry Hill, Newbury, Berkshire RG13 1JA. Telephone: Newbury (0635) 39000.

References: (1) Olive S et al, J Antimicrob Chemother 1983; 11 (Suppl B): 153-158. (2) Gaya H. Paper presented at the International Congress of Chemotherapy, Vienna 1983.

*European Organisation for Research on Treatment of Cancer.


® Registered trade mark of Bayer, Germany.

Bayer
ANTIBIOTICS



Dual Control

Two research based
organisations combine



—now—a comprehensive
treatment programme for
the British diabetic
patient.

SCRIBING INFORMATION VELOSULIN (Neutral Insulin Injection BP), INSULATARD (Isophane Insulin Injection BP), MIXTARD 30/70 (Neutral Suspension comprising 30% Neutral Insulin injection BP and 70% Isophane Insulin Injection BP), INITARD 50/50 (Neutral Suspension comprising 50% Neutral Insulin Injection BP and 50% Isophane Insulin Injection BP). Velosulin, Insulatard, Mixtard 30/70 and Initard 50/50 are manufactured from highly purified pork insulin. **PRESENTATION** Velosulin, Insulatard, Mixtard 30/70 and Initard 50/50 are available in 10ml vials containing 40 iu/ml, 80 iu/ml and 100 iu/ml, and are fitted with tamper-proof caps colour coded as follows:- 40 iu/ml - Blue. 80 iu/ml - Green. 100iu/ml - Orange. To provide sensory identification of insulin type, the metal sealing rings of the vial have tactile marks as follows:- Velosulin - one mark. Insulatard - two marks. Mixtard 30/70 - three marks. Initard 50/50 - four marks. **USES** Treatment of insulin Dependent Diabetics. Velosulin is particularly suitable in the treatment of diabetic coma and precoma. It may be mixed with Insulatard (NPH), Mixtard 30/70 or Initard 50/50 in all proportions without changing the characteristic effect of any of the types of insulin. (See Data Sheet for procedure). **DOSAGE AND ADMINISTRATION** Dosage to be determined by the physician.

The Nordisk and Wellcome Foundations in diabetes.


Nordisk Insulinlaboratorium, the Danish charitable Foundation, has been at the forefront of insulin innovation for sixty years. Through a dedicated research programme Nordisk has been first with slow-acting insulin preparations, first to concentrate production on pork and first to bring to patients and physicians the benefits of single-vial mixes.

The Wellcome Foundation is an acknowledged leader in research, and has been supplying the needs of the British diabetic patient for sixty years. Wellcome also continues to demonstrate an extensive commitment to postgraduate medical education throughout the United Kingdom.

The mutual co-operation of these two organisations creates a major force in diabetes therapy - with a flexible range of highly purified pork insulins now to appear under a combined Nordisk Wellcome label. Additionally, and importantly, the philosophy of both organisations extends to supportive care of the diabetic patient in the community together with a continuing nationwide series of educational courses and symposia for the professions.

Also, for the first time and as a result of this co-operation, part of the complex manufacturing process of these insulins will be carried out in the United Kingdom. Distribution of these insulins will be effected throughout this country and the Republic of Ireland by The Wellcome Foundation Ltd.

As may be expected of two highly regarded research based organisations, further important product developments will be announced under the Nordisk and Wellcome symbol, substantiating their claim that with proper care the effect of diabetes on quality of life can be further minimised.



Nordisk and Wellcome in diabetes Caring in concert

Further information is available from:

Nordisk-UK,
Highview House, Tattenham Crescent, Epsom Downs,
Surrey KT18 5QJ.
Telephone No: Burgh Heath (07373) 60621

The Wellcome Foundation Limited,
Crewe Hall, Crewe, Cheshire CW1 1UB.
Telephone No: Crewe (0270) 583151

THE BEST CHOICE EVERY TIME

IT WORKS In the treatment of ulcerative colitis, Colifoam is as effective as steroid enemas. At the same time it has been shown that patients find the foam easier to retain.^{1,2}

PATIENTS PREFER IT

Colifoam is far more comfortable, more convenient and more acceptable than enemas. Patients also find it easier to administer and that it causes less interference in their daily lives.

IT COSTS LESS

Surprisingly, despite the fact that it's just as effective and far more comfortable, Colifoam is less expensive. In fact, it can cost up to $\frac{1}{3}$ less per dose than a standard proprietary enema.³

IT'S SAFER

Recent clinical data shows Colifoam has extremely low levels of systemic absorption,⁴ lower than proprietary prednisolone enemas.⁵ Therefore, there is less potential for adrenal suppression which means that Colifoam may be considered safer in long-term use.

COLIFOAM

hydrocortisone acetate foam

IN DISTAL INFLAMMATORY BOWEL DISEASE. THE BEST CHOICE EVERY TIME.

Presentation White odourless aerosol foam containing hydrocortisone acetate Ph Eur 10%. **Uses** Anti-inflammatory corticosteroid therapy for the topical treatment of ulcerative colitis, proctosigmoiditis and granular proctitis. **Dosage and administration** One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with every pack). Satisfactory response usually occurs within five to seven days. **Contra-indications, warnings etc.** Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. **Pharmaceutical precautions** Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Shake vigorously before use. Keep out of reach of children. For external use only. **Legal category** POM. **Package quantities** Aerosol canister containing 25g (approx. 14 applications). **Basic NHS cost** 25g plus applicator, £7.40. **Further Information** One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. **Product Licence No.** 0036/0021. **References** 1. Ruddell WSJ et al. Gut 1980; 21: 885-889. 2. O'Donoghue D. Modern Medicine, December 1981; 45. 3. Source: Mims. 4. Barr WH, Kline B, Brightol L, Zfass A, Medical College of Virginia/Virginia Commonwealth University, FDA bioavailability submission document October 1981. 5. Lee DAH et al. Gut 1980; 21: 215-218. Further information is available on request. **Stafford-Miller Ltd.**, Professional Relations Division, Hatfield, Herts. AL10 0NZ.

THE ECLIPSE OF TODAY'S ANTIBIOTICS?

ANNOUNCING
A TRULY
REMARKABLE
CEPHALOSPORIN



NEW

FORTUM

ceftazidime

For the first time.
The bactericidal power
of aminoglycosides
and exceptional
antipseudomonal activity
from an extended spectrum
cephalosporin.

Hospital antibiotics created in Britain by



A TRULY REMARKABLE NEW CEPHALOSPORIN

FORTUM

ceftazidime

PRESCRIBING INFORMATION

Presentation

Fortum for Injection is supplied in vials containing 500mg, 1g and 2g ceftazidime (as pentahydrate) with sodium carbonate.

Uses

Fortum is a bactericidal cephalosporin antibiotic which is resistant to most beta-lactamases and is active against a wide range of Gram-positive and Gram-negative bacteria.

It is indicated for the treatment of single infections and for mixed infections caused by two or more susceptible organisms. Fortum, because of its broad antibacterial spectrum, may be used alone as first choice drug, pending sensitivity test results.

Dosage and administration

The usual adult dosage is in the range 1g to 6g i.m. or i.v. per day (see Data Sheet for details).

Contra-indication

Fortum is contra-indicated in patients with known hypersensitivity to cephalosporin antibiotics.

Precautions

Cephalosporins may, in general, be given safely to patients who are hypersensitive to penicillins. Care is indicated in patients who have experienced an anaphylactic reaction to penicillin.

Cephalosporin antibiotics at high dosage should be given with caution to patients receiving concurrent treatment with nephrotoxic drugs. Clinical experience with Fortum has shown that this is not likely to be a problem at the recommended dose levels. Reduce dosage when renal function is impaired (see Data Sheet).

As with all drugs, Fortum should be administered with caution during the early months of pregnancy and in early infancy. Fortum is excreted in human milk in low concentrations.

Fortum does not interfere with enzyme-based tests for glycosuria. Slight interference with copper reduction methods may be observed. Fortum does not interfere in the alkaline picrate assay for creatinine.

Fortum and aminoglycosides should not be mixed in the same giving set or syringe.

As with other broad spectrum antibiotics, prolonged use of Fortum may result in the overgrowth of non-susceptible organisms (e.g., *Candida*, *Enterococci*) which may require interruption of treatment or adoption of appropriate measures.

Side effects

Fortum is generally well tolerated with only infrequent adverse reactions, e.g., pain and/or inflammation after i.m. administration and phlebitis and/or thrombophlebitis after i.v. administration, rashes, fever, pruritis, gastro-intestinal disturbances, headache, dizziness, paraesthesiae and bad taste. Transient changes in laboratory values may occur including: eosinophilia, a positive Coombs' test, thrombocytosis and slight rises in hepatic enzymes.

Basic NHS cost (exclusive of VAT)

The basic NHS cost of Fortum is £9.90 per gram.

Available in packs of: 5 x 500mg, 5 x 1g and 5 x 2g vials and an infusion pack of 5 x 2g vials.

Product Licence numbers

500mg: 0004/0292

1g: 0004/0293

2g: 0004/0294

Further information is available on request from:

Glaxo

Glaxo Laboratories Limited, Greenford, Middlesex UB6 0HE

Fortum is a Glaxo trade mark.

Hospital antibiotics created in Britain by



Carcinoma of the Liver, Biliary Tract and Pancreas

Edited by J.-C. Gazet

Management of Malignant Disease Series

A timely review of the present methods of management, both surgical and non surgical, of tumours in the liver, gall bladder, bile ducts and pancreas.

£15 boards 208 pages

Ophthalmic Anaesthesia

G. Barry Smith

The only book on ophthalmic anaesthesia available in the English language. It brings anaesthetists up-to-date with the recent advances brought on by the significant changes in ophthalmic surgery over the last five years.

£9.95 paper 88 pages



Edward Arnold
41 Bedford Square, London WC1B 3DQ

ANTI-MALIGNIN ANTIBODY DETERMINATION

Now available to laboratories

Anti-Malignin Antibody (AMA) (tm) is the serum antibody to the structurally defined polypeptide general transformation antigen Malignin (tm) and related cancer Recognins (tm) present in cancer cells⁽¹⁻⁶⁾.

DIAGNOSTIC AID

AMA is elevated in 93% of active cancer patients regardless of the cell type.

The overall incidence of asymptomatic or false positive results in 1,241 controls in four independent blind studies is low (5.2%)⁽¹⁻⁶⁾. AMA therefore can be of value as a diagnostic aid.

MONITORING

The AMA level is quantitatively related to survival⁽²⁻⁶⁾. Also, in successfully treated cancer patients with no further evidence of disease AMA returns to normal levels in 97% of cases⁽⁴⁻⁶⁾. AMA therefore can be useful in monitoring the effect of treatment and patient progress.

Interested laboratories should contact

ONCOLAB LIMITED
93 Harley Street, London W1N 1DF
Tel: 01-935 9880

References:

1. Nat. Cancer Institute Mon. 46, 133-137, 1977.
2. Lancet 1,987, 1979.
3. Lancet 1,141, 1981.
4. J. Medicine 13,49-69, 1982.
5. Protides of Biol. Fluids (Pergamon) 337-352, 1982.
6. SmithKline Clinical Laboratories Study, Preprint 1983 (available on request).

NOCTAMID'S HYPNOTIC DURATION IS CLOSE TO IDEAL



Very short-acting hypnotics
cannot ensure a full night's sleep and may cause rebound anxiety¹.

Noctamid. 6-8 hours
normal sleep² without impaired daytime performance.³

Long-acting hypnotics
can impair performance the following day⁴ and tend to accumulate in the body.¹

NOCTAMID 1mg NOCTE

lormetazepam

FAST ASLEEP ALL NIGHT-WIDE AWAKE ALL DAY

Abbreviated Prescribing Information. **Presentation:** Tablets containing 1mg and 0.5mg lormetazepam. **Indication:** Short-term treatment of insomnia. **Dosage:** Adults: 1mg. Elderly patients: 0.5mg. **Contra-indications:** Known sensitivity to benzodiazepines. Myasthenia gravis. **Precautions:** Noctamid, other centrally-acting drugs and alcohol enhance each other's actions. Users should beware of dizziness or drowsiness when driving or operating machinery. Use during pregnancy is not recommended. Prolonged high dosage may occasionally cause psychological dependence. **Possible side effects:** Include headaches, nausea, drowsiness, blurring of vision, dizziness and ataxia. More severe psychological and physical side-effects have been known to occur rarely with some benzodiazepines, but have not been reported with Noctamid. **Legal category:** POM. **Product licence no.** 0.5mg 0053/0117. 1mg 0053/0118. **Product licence holder:** Schering Chemicals Limited, The Brow, Burgess Hill, West Sussex RH15 9NE. **Basic NHS price:** 1mg/30 tablets: £2.23. 1mg/100 tablets: £7.44. 0.5mg/30 tablets: £1.62. 0.5mg/100 tablets: £5.40. **References:** 1. Oswald I. Psychiatry in Practice 1982; 1 (12): 8-13. 2. Jovanovic U J et al. Waking and Sleeping 1980; 4: 223-225. 3. Heidrich H et al. Int J Clin Pharmacol Ther Toxicol 1981; 19 (1): II-19. 4. Br Med J 1980; 3: 743. Full prescribing information is available on request.

Schering

Wellcome introduces CEFIZOX

ceftizoxime sodium

expect



Prescribing information:

Presentation: Vials containing 500mg, 1g and 2g of ceftizoxime as the sterile sodium salt.

Uses: Broad-spectrum, bactericidal, cephalosporin antibiotic. Indications include lower respiratory tract infections, genito-urinary tract infections including gonorrhoea, intra-abdominal infections, septicaemia, skin and soft tissue infections. Cefizox is active against a wide range of Gram-positive and Gram-negative organisms and is stable to a broad spectrum of beta-lactamases produced by both aerobic and anaerobic organisms.


by continuous or intermittent intravenous infusion, or by deep intramuscular injection. For reconstitution details see Data Sheet. Modification of the following guideline dosages is necessary in patients with impaired renal function (see Data Sheet).

Adults: urinary tract infection, 0.5-1g 12-hourly, IM or IV; gonorrhoea, 1g single dose, IM; other infections, 1-2g 8-12 hourly, IM or IV; severe or life-threatening infections, 2-3g 8-hourly, IM or IV. **Children over the age of 3 months:** 30-60 mg/kg bodyweight/day in 2-4 divided doses, increased in severe or life-threatening infections to 100-150mg/kg bodyweight/day. The total dose should not exceed the adult dose. *Under the age of 2 months insufficient data to recommend use.*

Contra-indications: Hypersensitivity to cephalosporin antibiotics.

Precautions: Renal status should be monitored, especially in seriously ill patients receiving maximum dose therapy and co-administration of aminoglycoside antibiotics. Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides. As with any other antibiotic, prolonged use may result in overgrowth of non-susceptible organisms. Caution in penicillin-sensitive patients because of possible cross-reaction.

Side- and adverse effects: Cefizox is generally well



The excellent *in vivo* performance of Cefizox is the sum of many factors. Most notably, its powerful spectrum of antibacterial activity, stability to β -lactamases, and highly effective tissue penetration.

Potent antibacterial spectrum

Cefizox is a powerful, third-generation, injectable cephalosporin. It has a wide spectrum of activity against both Gram-negative and Gram-positive aerobic and anaerobic organisms including *E. coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *H. influenzae*, *Strep. pneumoniae*, *Staph. aureus* and *Strep. pyogenes*.^{1,2}

It is also active against hospital opportunist pathogens not so frequently encountered, such as indole-positive *Proteus*, *Serratia marcescens*, *Morganella morganii*, and *Enterobacter*.^{1,2}

Superior β -lactamase stability

Cefizox has excellent β -lactamase stability, and is resistant to a wider range of β -lactamases than cefotaxime.³

Excellent tissue penetration

After a single dose, concentrations of Cefizox in most tissues and body fluids are easily in excess of the MIC of likely pathogens.

Study has shown that Cefizox achieves greater concentration in most tissues and body fluids than cefotaxime, after equivalent doses.⁴

And, unlike cefotaxime, Cefizox is not metabolised.⁵ Thus the full therapeutic effect of Cefizox is maintained.

International clinical success

Extensive experience confirms that Cefizox provides excellent clinical results against opportunist hospital pathogens.

It has been shown to be highly effective in lower respiratory tract infections, genito-urinary tract infections including gonorrhoea, intra-abdominal infections, septicaemia, and skin and soft tissue infections.²

Cefizox has also been notably successful in treating infections resistant to ampicillin, carbenicillin, cefamandole, tobramycin or gentamicin.⁶

And Cefizox has proved suitable for use in neutropenic patients⁷ and children.⁸

With a broad spectrum of antibacterial activity, proven efficacy and a low level of side effects,⁹ Cefizox is a logical choice in serious infection. Especially before the infecting organism is identified, where multiple infection is suspected, or the infection is resistant to other cephalosporins, aminoglycosides or penicillins.

When infection threatens, Cefizox is an excellent choice.

CEFIZOX

cefizoxime sodium

References 1 Barry, A.L. *et al* (1982), *J. Antimicrob. Chemother.* **10**, Suppl. C, 25. 2 Parks, D. *et al* (1982), *ibid.*, 327. 3 Simpson, I.N. *et al* (1982), *J. Antimicrob. Chemother.* **9**, 357. 4 Gerding, D.N. and Peterson, L.R. (1982), *J. Antimicrob. Chemother.* **10**, Suppl. C, 105. 5 Quintilianni, R. and Nightingale, C.H. (1982), *ibid.*, 99. 6 Neu, H.C. (1982), *ibid.*, 193. 7 Lawson, R.D. and Baskin, R.C. (1982), *ibid.*, 159. 8 Shikuma, C.M. *et al* (1982), *ibid.*, 293. 9 Platt, R. (1982), *ibid.* 135. Cefizox is a Trade Mark.

tolerated. The most common adverse reactions have been local following IM or IV injection. These include burning, cellulitis, pain, induration, tenderness, paraesthesia and phlebitis. Other adverse reactions include hypersensitivity reactions (rash, pruritis, fever), gastrointestinal disturbance (diarrhoea, nausea, and vomiting), vaginitis, transient eosinophilia, thrombocytosis. Neutropenia, leucopenia and thrombocytopenia have been reported rarely. Some individuals have developed a positive Coombs' test. Transient elevation in SGOT, SGPT, alkaline phosphatase, BUN and serum creatinine have occasionally been observed.

Use in pregnancy and lactation. There are no data in

pregnant women, thus the benefit of using Cefizox in pregnancy should be weighed against the possible hazard. Caution should be exercised if Cefizox is administered to a nursing mother.

Basic NHS costs:

1 x 500mg vial (PL3/0174)	£2.76
1 x 1g vial (PL3/0175)	£5.50
1 x 2g vial (PL3/0175)	£11.00

Further information is available on request.

Wellcome Medical Division

Made by Fujisawa Pharmaceutical Co Ltd, Osaka, Japan, for The Wellcome Foundation Ltd, London.




Wellcome



Fujisawa

An important additional benefit for Hypovase®...



...restoring the plasma lipid ratio.

Already firmly established as a booster therapy in hypertension and in the treatment of congestive heart failure, Hypovase has now been shown to have an additional beneficial property... the restoration of the plasma lipid ratio.¹

This is important because the use of the first line anti-hypertensives such as β -blockers and diuretics has not reduced the incidence of ischaemic heart disease (IHD).²⁻⁵

One possible reason is that their beneficial effects on blood pressure, one risk factor for IHD, have been offset by their

effect on another major risk factor – the plasma lipid ratio (HDL: LDL & VLDL).⁶⁻⁹

Hypovase when added to these first line anti-hypertensives restores the plasma lipid ratio, providing yet another good reason for adding Hypovase to your first line therapy.

Hypovase®

prazosin HCl

**a dual role in hypertension,
an important role in congestive
heart failure.**

Prescribing Information: Indications Hypertension of varied aetiology and all grades of severity, congestive heart failure of moderate to severe degrees. **Contra-contraindications** Sensitivity to Hypovase. **Precautions** A low initial dose and gradual titration is recommended. A small percentage of patients may react more rapidly and to a greater extent than the majority. In some cases this has led to sudden loss of consciousness generally lasting a few minutes.

Subsequent treatment may be satisfactory. Hypovase is not recommended in pregnancy, during lactation or in children under 12 years of age. **Side Effects**

Dizziness, drowsiness and lack of energy are the most common. **Dosage: Congestive Heart Failure** Suggested Initial Daily Dose Range: 0.5mg increasing to 1.0mg t.i.d. or q.i.d. Usual Daily Maintenance Dose:

4.0mg to 20mg in divided doses. **Hypertension** Starting dose 0.5mg two to three hours before retiring; thereafter up to 20mg/day in divided doses. Twice daily dosing is usually adequate. **Basic N.H.S. Cost** 0.5mg tablet (PL57/0149) pack of 100, £4.08; 1mg tablet (PL57/0106) pack of 100, £5.25; 2mg tablet (PL57/0107) pack of 100, £6.98; 5mg tablet (PL57/0108) pack of 100, £15.58.

Also available is a b.d. Starter Pack, for hypertension only, containing 8 x 0.5mg and 32 x 1mg Hypovase tablets, £2.70.

REFERENCES: 1. Leren, P, Eide, I, Foss, O.P, Helgeland, A, Hjermann, I, Holme, I, Kjeldsen, S. E, The Oslo Study, Lancet, July 5th, 1980; 2: 4-6. 2. Medical Research Council Working Party, Lancet 1981, II, 539-543. 3. Veterans Administration Co-operative Study Group,

JAMA, 1970; 213: 1143-1152. 4. Hypertension Detection and Follow-up programme Co-operative group, JAMA, 1979; 242: 2560-2577. 5. Australian National Blood Pressure Study Management Committee, Lancet, 1980, I, 1261-1267. 6. Johnson, B. F, Journal of Cardiovascular Pharmacology, 1982, 4, Suppl. 2: S213-221. 7. Kaplan, N. M., Journal of Cardiovascular Pharmacology, 1982, 4, Suppl. 2: S187-189. 8. Oliver, M. F, New England Journal of Medicine 1982; 306, No. 5: 297-298. 9. Lowenstein, J., Neusy, A. J, Journal of Cardiovascular Pharmacology, 1982; 4, Suppl. 2: S262-264.

Full information on request.
Pfizer Ltd, Sandwich, Kent.
*Trade Mark. 20868

Pfizer

When the first bronchodilator isn't enough...

it's time to add
TWICE DAILY
INHALED
Becotide
(Beclomethasone Dipropionate BP)
not another
bronchodilator

There are few asthmatics more at risk than the undermedicated child and yet undertreatment of childhood asthma is the disturbing conclusion reached in a recent survey.¹

Becotide is capable of producing a significant improvement in childhood asthma, enabling them to achieve adult life without impairment of their educational and career prospects.²

1. Speight ANP *et al.* Br. Med. J. 1983; 286: 1,253-58.

2. Morrison Smith J. In: *Steroids in Asthma*. Chap. XII; ADIS Press Limited, Auckland, NZ. 1983: 192-200.

Prescribing Information **Uses:** Bronchial asthma especially in patients whose asthma is not adequately controlled by bronchodilators. **Dosage and administration:** **Becotide Inhaler** – **Adults:** 4 puffs twice daily or 2 puffs four times daily is the usual maintenance dose. Severe cases, initially 12-16 puffs daily, reducing according to response. **Children:** 1 or 2 puffs two to four times daily.

Becotide Rotacaps – **Adults:** 400 micrograms twice daily or 200 micrograms four times daily is the usual maintenance dose. **Children:** 100 micrograms two to four times daily. **Contra-indications:** None known but special care is necessary in patients with active or quiescent pulmonary tuberculosis. **Precautions:** A short course of oral steroids in addition to Becotide may be required in patients with excessive mucus in the respiratory tract. Unnecessary administration of drugs during the first trimester of pregnancy is undesirable. Transfer of patients to Becotide from systemic steroid therapy requires special care – see data sheet for detailed procedure. **Side effects:** Occasional candidiasis in some patients. **Presentation and basic NHS cost:** Becotide Inhaler is a metered-dose aerosol delivering 50 micrograms Beclomethasone Dipropionate BP per actuation. Each canister containing 200 inhalations, £4.77. Becotide Rotacaps 100 micrograms 200 micrograms each contain a mixture of the stated amount of microfine Beclomethasone Dipropionate BP and larger particle lactose in buff/colourless and brown/colourless hard gelatine capsules. Containers of 100, £7.26 and £9.67 respectively. Becotide Rotahaler for use with Becotide Rotacaps 78p.

Product licence numbers: Becotide Inhaler 0045/0089, Becotide Rotacaps 100 micrograms 0045/0119, Becotide Rotacaps 200 micrograms 0045/0120.



Further information is available on request from:


Allen & Hanburys Limited, Greenford, Middlesex UB6 0HB

Becotide, Rotacap and Rotahaler are trade marks

AUGM

THE SUPERIOR SPECTRUM AGAINST MORE THAN OTHER STANDARD C

Activity against urine isolates from hospital in-patients.¹



Superior spectrum of activity

Results of tests involving over 1,700 urinary isolates clearly demonstrate the excellent *in-vitro* activity of Augmentin compared to the other commonly-used oral antibacterials shown.

Excellent clinical performance

In one study² Augmentin was used to treat 96 patients with urinary tract infections. In spite of multiple antibiotic resistance, the cure rate during treatment was 92% and even at one month post-treatment had fallen to only 69%. Augmentin is an effective, inexpensive and convenient alternative to injectable antibiotics.

Double-blind trial of Augmentin and amoxycillin

In a double-blind trial of 234 patients with complicated urinary tract infections, Augmentin was found to be significantly more effective than amoxycillin.³

Penicillin-based therapy

Augmentin has been shown to be well-tolerated as would be expected from a penicillin-based antibiotic.⁴


Prescribing Information

USES: Chest. ENT. Genito-urinary tract. Skin and soft tissue infections.

DOSAGE: Adults and children over 12 years: One Augmentin or Augmentin Dispersible Tablet (375 mg) three times a day. Children 6-12 years: 5 ml Augmentin Junior Suspension (187 mg) three times a day. Children 2-6 years: 5 ml Augmentin Paediatric Suspension (156 mg) three times a day. Children 9 months-2 years: 5 ml half-strength Augmentin Paediatric Suspension (78 mg) three times a day. Children 3-9 months: 2.5 ml half strength Augmentin Paediatric Suspension (39 mg) three times a day. In severe infections, dosages for patients aged 2 years and over, may be doubled. Treatment with Augmentin should not be extended beyond 14 days without review.

CONTRA-INDICATION: Penicillin hypersensitivity.

PRECAUTIONS: Safety in human pregnancy is yet to be established. Dosage need not be reduced in patients with renal impairment, unless dialysis is required.





AUGMENTIN THE PROMISE OF SUCCESS FOR MORE PATIENTS.¹

SIDE-EFFECTS: Uncommon, mainly mild and transitory, eg diarrhoea, indigestion, nausea, vomiting, candidiasis, urticarial and erythematous rashes. If gastro-intestinal side-effects occur, they may be reduced by taking Augmentin at the start of meals.

PRESENTATIONS: (Prices correct at October, 1983.) ▼ **Augmentin Tablets and Dispersible Tablets**,

each providing 125 mg clavulanic acid with 250 mg amoxycillin. Augmentin Tablets (bottles of 30, 100).

Cost per tablet - 29p PL0038/0270. Augmentin Dispersible Tablets (foil wrapped 30, 90). Cost per tablet - 32½p PL 0038/0272. ▼ **Augmentin Junior Suspension**. Powder to prepare 100 ml suspension.

Each 5 ml provides 62 mg clavulanic acid with 125 mg amoxycillin. Cost per 5 ml dose - 18p PL0038/0274. ▼ **Augmentin Paediatric Suspension**. Powder to prepare 100 ml suspension. Each 5 ml

provides 31 mg clavulanic acid with 125 mg amoxycillin. Cost per 5 ml dose - 14p PL0038/0298.

The clavulanic acid is present as potassium clavulanate and the amoxycillin as the trihydrate. All the

above presentations are sugar-free formulations.

References 1. Data published in summary form in: Proceedings of the First Augmentin Symposium. Rolinson, G.N. and Watson, A. (eds), Excerpta Medica, 1980, pp 173-183. 2. J. Antimicrob. Chemother., 1981, 7, 229-236. 3. Proceedings of the Second Augmentin Symposium, Leigh, D.A., Robinson, O.P., (eds) Excerpta Medica, 1981, pp 86-95. 4. Ibid., p244.

Further information is available on request to the Company.

Beecham Research Laboratories, Brentford, England.
Augmentin and the BRI logo are trade marks.



Depression A Constant Source of Anxiety



PROTHIADEN A Consistent Source of Effective Treatment

Prothiaden is an efficient, well tolerated antidepressant with a significant anxiolytic action. It achieves consistently good results in a wide variety of depressive states — including those with associated anxiety — and in patients of all ages. Which is why Prothiaden is now the most widely prescribed antidepressant in the United Kingdom.

Prescribing Information

Presentation: Prothiaden is Dothiepin Hydrochloride B.P., an antidepressant of the tricyclic group. It is available as 25mg capsules and 75mg tablets. **Uses:** Prothiaden is indicated in the treatment of depression and associated anxiety. **Dosage:** Prothiaden should be given in a dosage of 75 to 150mg daily, based on response and severity. This may be taken as a single evening dose. In certain circumstances, i.e. in hospital use, Prothiaden has been given in dosages up to 225mg daily. **Elderly:** half the normal adult dose may be sufficient. **Precautions and Contra-Indications:** Prothiaden has anticholinergic properties; therefore, it may precipitate urinary retention in susceptible individuals and its use should be avoided in patients with existing or potential urinary retention. Prothiaden should not be used in patients with closed-angle glaucoma. Caution is advised when treating epileptic patients and those with cardiovascular disorders. Prothiaden should not be used with MAO inhibitors nor within 14 days of ceasing such treatment. It may modify the action of some CNS depressants, catecholamines and hypotensive agents. **Side Effects:** These are usually mild and normally controlled by reducing the dosage. The following have been reported: dryness of mouth, constipation, disturbed accommodation, orthostatic hypotension, palpitations, somnolence, tremor, headache. **Basic N.H.S. Price:** 28 x 75mg £2.61. **Product Licence Numbers:** PL0014/5941, PL0014/0209.



The Boots Company PLC, Nottingham, England. Further information available on request.

PROTHIADEN

Dothiepin Hydrochloride B.P.

The Dependable Antidepressant

BOOKS FROM THE BMA**Special announcement to readers overseas . . .**

From 1 January 1984 we are introducing a new price structure for most of the BMA books.

A selection of books with the new prices is listed below:

	Price to non-members		Price to members	
	£	US\$	£	US\$
New Drugs	7.50	13.00	7.00	12.00
Aviation Medicine	7.50	13.00	7.00	12.00
Practising Prevention	7.50	13.00	7.00	12.00
Sex Problems in Practice	6.00	10.00	5.50	9.00
Emergencies in the Home	7.50	13.00	7.00	12.00
Statistics at Square One	4.50	8.00	4.00	7.00
How To Do It	7.00	13.00	6.50	12.00
Epidemiology for the Uninitiated	4.50	8.00	4.00	7.00

ABC SERIES

ABC of Computing	8.00	14.00	7.50	13.00
ABC of Healthy Travel	6.00	10.50	5.50	9.50
ABC of Brain Stem Death	7.50	13.00	7.00	12.00
ABC of Diabetes	6.50	11.50	6.00	10.50
Alcohol Problems	8.00	14.00	7.50	13.00
Statistics in Practice	11.00	19.00	10.00	17.50
The First Year of Life	8.00	14.00	7.50	13.00
ABC of 1 to 7	11.75	20.50	10.75	19.00
Procedures in Practice	7.00	13.00	6.50	12.00
ABC of Ear, Nose and Throat	6.00	10.50	5.50	9.50
ABC of Hypertension	6.00	10.50	5.50	9.50
ABC of Ophthalmology	5.50	9.50	5.00	8.50

Payment

All areas, except the USA: Payment should be made in sterling on a bank in the United Kingdom.

USA: Payment should be made in US dollars, on a bank in the United States of America, or in sterling on a bank in the United Kingdom.

Payment must be enclosed with order. BMA members must quote their membership number.

All books are despatched by air

Please contact the Subscription Manager for a book catalogue and complete list of publications.

ORDER FROM: The Subscription Manager, BRITISH MEDICAL JOURNAL, BMA House, Tavistock Square, London WC1H 9JR, or any leading medical bookseller.


LETTERS TO A YOUNG DOCTOR

PHILIP RHODES

Faced with increasing competition and even the prospect of unemployment young doctors need sound advice on how they should plan their careers. This series of articles by Professor Philip Rhodes, begins with advice to preregistration house officers and then considers the choice open to them after registration. There are sections on study leave, applying for jobs, and interviews, and chapters giving special advice to women and overseas doctors. Examinations, research, teaching, administration, and postgraduate education are also covered.

Price: Inland £6.00
Overseas £8.00/USA\$14.00
(Inland £5.50;
Overseas £7.50/USA\$13.00
to BMA members)
Despatched by air overseas
Payment must be enclosed with order

Order your copy now
From: The Publisher
British Medical Journal
BMA House
Tavistock Square
London WC1H 9JR
or any leading bookseller



Just published

AVIATION MEDICINE

Richard M Harding & F John Mills


This authoritative and highly readable account of the little known specialty of aviation medicine will interest both general readers and those interested in it as a career. Comprehensive information on the management of airline passengers with particular medical conditions before, during, and after flight will help doctors faced with deciding whether or not their patient is fit to fly and with coping with a medical emergency in the air while themselves passengers on board an aircraft. The chapters on the problems of altitude, acceleration, the function of the special senses in flight, special forms of flight, and aviation psychology describe clearly and precisely the physiological and behavioural effects that flight imposes on man.

Price: Inland £5.50;
Overseas £7.50/USA\$13.00
(Inland £5.00;
Overseas £7.00/USA\$12.00 to
BMA members)

Despatched by air overseas

Payment must be enclosed with order

Order your copy now
From: The Publisher
British Medical Journal
BMA House
Tavistock Square
London WC1H 9JR
or any leading bookseller



ALCOHOL PROBLEMS

In recent years alcohol problems have increased dramatically and the thinking on them has undergone a revolution. Alcohol Problems brings together two series of articles published in the *BMJ*—the ABC of Alcohol, with its emphasis on straightforward advice for the clinician, and Alcohol and Alcoholism, Dr Richard Smith's more discursive survey of current thinking and controversies. Together they cover both the clinical aspects of managing alcohol problems and the social and political factors that surround them.


Price: Inland £5.50
Overseas £8.00/USA\$14.00
(Inland £5.00;
Overseas £7.50/USA\$13.00
to BMA members)

Despatched by air overseas

Payment must be enclosed with order

Order your copy now

From: The Publisher
British Medical Journal
BMA House
Tavistock Square
London WC1H 9JR
or any leading bookseller



“... a good account of the right kinds of observations to make in order to detect people with alcohol problems... These articles are succinct and well written and provide the best source of information and reference for general practitioners and trainees. This is an outstanding series which will be of great value to everyone concerned with the prevention, identification and management of alcohol-related problems.”


Update 1983; 26: 301

For the hurting hip

To your patient, arthritis means pain and the right treatment is that which brings quick and sustained relief.

Froben brings the pain of arthritic joints under control within hours and maintains that control for as long as is needed. For months. If necessary, for years.

Powerful, yet well tolerated, Froben provides the sustained, consistent relief of pain which must be the right treatment for arthritis. With Froben, the treatment is right from the start.



Start with

the undoing of arthritic pain

Froben

flurbiprofen

Prescribing Information

PRESENTATION: Sugar-coated tablets, each containing either 50 or 100mg of flurbiprofen. **USES:** Froben is indicated in the treatment of rheumatoid disease, osteoarthritis and ankylosing spondylitis. **DOSAGE:** 150 to 200mg daily in 3 or 4 divided doses. In patients with severe symptoms, particularly during acute exacerbations, the daily dose may be increased to 300mg in divided doses. **CONTRA-INDICATIONS:** **WARNINGS etc:** Froben should not be given to patients with peptic ulceration and inflammatory bowel disease, or to patients with a history of asthma or who have experienced bronchospasm or other hypersensitivity-type reactions with other anti-inflammatory agents. The safety of Froben during pregnancy or lactation has not been established. In animal experiments, no teratogenic effects were demonstrated but parturition was delayed and prolonged. Froben may prolong bleeding time and cause fluid retention. Use with caution where renal function is impaired. Side effects: Dyspepsia, heartburn and headache are the commonest encountered. Gastrointestinal haemorrhage, diarrhoea, mouth ulcers, peptic ulceration and skin rashes have been reported. Very rarely cholestatic jaundice and blood dyscrasias have been reported but these reactions do not seem causally related. Drug interactions: The effect of anti-coagulants may be increased and oral diuretics may be reduced. Treatment of Osteoporosis: Generic levon and, if necessary, correction of serum electrolytes. There is no specific antidote. **BASIC N.H.S. PRICE:** 50mg tablets, 100 £2.24; 100mg tablets, 100 £15.65. **PRODUCT LICENCE No:** 50mg tablets, PL0014/0167; 100mg tablets, PL0014/0168.



The Boots Company PLC, Nottingham, England.

Further information available on request


A prescription for Ventide provides comprehensive maintenance for chronic asthma.

Since Verolin and
aztreonam are used to control your patient's
asthma, it is important that both
drugs are taken regularly.

By combining Ventolin and Becotide in one inhaler Ventide provides the same therapy with half the number of inhalations.

Compliance with maintenance therapy in chronic asthma can therefore be improved by prescribing Ventide.

Ventide should not be taken instead of Ventolin for the treatment of acute attacks.



Venice

(Salbutamol BP & Beclomethasone Dipropionate BP)

A logical combination

Prescribing information

replacement for systemic steroids are given in the Data Sheet for Beclotide Inhaler. Patients who have been weaned in the previous few months from long-term systemic corticosteroids need special consideration until the hypothalamic-pituitary-adrenal system has recovered sufficiently to enable the patient to cope with emergencies such as trauma, surgery or infections. Such patients should carry a warning indicating that they need supplementary systemic steroid during periods of stress, until their adrenocortical function has become normal. These patients should also be given a supply of oral steroid to use in emergency when their airways obstruction

worsens. *Conversely, the more the government tries to regulate the economy, the worse it gets.*

Special care is necessary in patients with active or quiescent pulmonary tuberculosis. Meticulous inhalation should be administered to patients suffering from thyrotoxicosis.

Unnecessary administration of drugs during the first trimester of pregnancy is undesirable.

© 1996 by the American Academy of Allergy, Asthma and Immunology. All rights reserved. 0882-5963/96/4104-0001\$3.00/0

Contraction of the larynx and closure of the glottis results in a closure of the mouth and throat (pharynx) occurs in some bacteria.

19. *Leucosia* (Leucosia) *leucostoma* (Fabricius) (Fig. 19)

the same time, the author has to topicalize the characters.

10. *Leucosia* (Leucosia) *leucostoma* (Fabricius) (Fig. 10)

Journal of Clinical Anesthesia, 1993, 5 (Supplement 2), 207-212. © 1993 Marcel Dekker, Inc. Contribution of RBC and RBC substitutes.

Digitized by srujanika@gmail.com University of Hyderabad, Hyderabad, India Basic AMS

10. *Leucosia* (Leucosia) *leucostoma* (Fabricius) (Fig. 10)

10. *W. C. Gandy, Jr.* (1970) *On the History of the Calculus* (Dover, New York).

10. *Leucosia* (Leucosia) *leucostoma* (Fabricius) (Fig. 10)

10. *Leucosia* (Leucosia) *leucostoma* (Fabricius) (Fig. 10)

19. *Leucosia* (Leucosia) *leucostoma* (Fabricius) (Fig. 19)

Digitized by srujanika@gmail.com

The liquid life-line



**A range of nutritionally balanced, complete tube feeds,
ready-to-use, in 500ml bottles.**

Cow & Gate Limited, Clinical Products Division, Cow & Gate House, Trowbridge, Wiltshire. BA14 8YX

DID YOUR LAST FAMILY HOLIDAY MATCH UP TO OURS?

Was your last family holiday abroad all that it might have been? Compare it to ours, we set the standards. Send for our exclusive 1984 brochure and start planning for a real family holiday that just cannot be matched.

Canvas Holidays 

Canvas Holidays Ltd., Bull Plain, Hertford, Herts. SG14 1DY. Tel. Hertford (0992) 59933.

A SCIENTIFIC SPRING BREAK IN CAMBRIDGE

The BMA will be holding a Scientific Meeting from the 12th to 14th April at Churchill College, Cambridge. The Meeting will be opened with an Address on "Medical Education" by Professor Sir John Butterfield, Regius Professor of Physic, University of Cambridge and there will be sessions on "In Vitro Fertilisation, Immediate Medical Care, Day-Case Surgery, Lasers in Medicine, Comparative Medicine and Transplant Surgery". The Scientific Meeting has been approved for zero-rating under the Section 63 regulations for three and a half sessions.

A registration fee of £25 will be charged for BMA members (£50 for non members) and this will be incorporated into residential charges for those staying at Churchill College. The programme for Accompanying Persons will include an all day tour to Suffolk Wool Towns and a half-day walking tour of Cambridge Colleges. Dinners will be held at both Churchill and King's College, Cambridge.

Further details of this Meeting may be obtained by writing to Miss Jill Draper, Annual Meetings Officer, BMA House, Tavistock Square, London WC1H 9JP.



*Physiological Principles in
Medicine Series*

Respiratory Physiology

John Widdicombe and Andrew Davies
A complete course in respiratory physiology presented at a level suitable for preparation for the 2nd MB examination. A unique feature of this text is its close integration with the clinical companion *Respiratory Disorders*.

£4.95 paper 128 pages illustrated

Respiratory Disorders

Ian R. Cameron and Nigel T. Bateman
This book enables students to relate the diseases which they encounter in their clinical training to the physiological principles learned in the basic science course.

£5.95 paper 144 pages illustrated



Edward Arnold
41 Bedford Square, London WC1B 3DQ

Just published

NEW DRUGS

In the past few years the number of important new drugs and our understanding of pharmacology have continued to increase. Reliable and unbiased information on the therapeutic use of these agents is, however, not always readily available. Articles recently published in the *BMJ* on entirely new groups of drugs – H₂ receptor antagonists, calcium antagonists, captopril – and on new members of groups of drugs already available – beta-blockers, tranquillisers, hypnotics, diuretics – fill this gap and are now collected together in book form. Busy practitioners will find that this comprehensive review allows them to make a more rational choice of treatment.

Price: Inland £6.50; Overseas £7.50/USA\$13.00
(Inland £6.00; Overseas £7.00/USA\$12.00
to BMA members)


Despatched by air overseas

Payment must be enclosed with order

Order your copy now

From: The Publisher, British Medical Journal
BMA House, Tavistock Square, London WC1H 9JR
or any leading bookseller

NEW DRUGS



ARTICLES FROM
THE BRITISH
MEDICAL JOURNAL

■ SHORT LISTED FOR THE
ABBOTT PRIZE FOR
MEDICAL WRITING

COMMON VERTEBRAL JOINT PROBLEMS

Gregory P. Grieve

592 PAGES 230 HALFTONE AND 101 LINE
ILLUSTRATIONS HARDBACK £32.00

A unique book which will be of immense value to all those concerned with the management of spinal joint problems whatever their clinical status.

Churchill
Livingstone

Robert Stevenson House, 1-3 Baxter's Place, Leith Walk,
Edinburgh EH1 3AF.

THE ROYAL COLLEGE OF SURGEONS OF EDINBURGH SPECIALTY FELLOWSHIP IN CARDIOTHORACIC SURGERY – FRCSED (C/Th)

A diet of the Specialty Fellowship Examination in Cardiothoracic Surgery will be held on 1 May 1984.

Candidates who should normally hold a Diploma of Fellowship of a Surgical College or an equivalent Diploma are required to have three years' post-Fellowship experience in Cardiothoracic Surgery of which one year must have been completed in an approved centre in the United Kingdom. Candidates must submit written evidence of their experience in the specialty including their operative experience.

The application form, examination calendar and Regulations are available on request from the:

**Examinations Secretary,
The Royal College of Surgeons of Edinburgh,
Nicolson Street, Edinburgh EH8 9DW.**

Applications for entry must be received by 16 March 1984. Fee: £135.

new
product
for Angina

Monit

Isosorbide mononitrate 20mg, Stuart

PREDICTABLE
ANGINA PROPHYLAXIS

♥
Usually 1b.d.

♥
Effective.

♥
For a wide range of patients.

Prescribing Information

Presentation 'Monit' tablets are white, round, scored tablets embossed 'Stuart 20'. Each tablet contains 20mg isosorbide mononitrate. **Uses** Prophylaxis of angina pectoris. **Mode of Action** Isosorbide mononitrate is an active metabolite of isosorbide dinitrate and from an oral dose exerts qualitatively similar effects. However, unlike the dinitrate which is subject to extensive 'first pass' hepatic metabolism, it has virtually complete systemic availability from an oral dose. Isosorbide mononitrate thus achieves predictable and sustained blood levels. Onset of pharmacological action occurs within 20 minutes of an oral dose and is maintained for more than 8 hours. **Dosage and Administration** Usually one tablet twice or three times daily. Patients already accustomed to prophylactic nitrate therapy (for example with isosorbide dinitrate) may normally be transferred directly to a therapeutic dose of 'Monit'. For patients not receiving prophylactic nitrate therapy, it is recommended that the initial dose should be half a tablet twice daily. Maintenance dose in individual patients will be between 20 and 120mg daily. The tablets should be swallowed whole with a little fluid. **Contra-indications, Warnings, etc.** **Contra-indications:** A known sensitivity to the drug or to isosorbide dinitrate. **Warnings:** The following adverse effects may be seen with nitrate therapy. 1. Cutaneous vasodilation, headache, dizziness and weakness may occur, and are usually controlled by lowering the dose. The incidence of these effects is highest at commencement of treatment and tends to decline with time. 2. Postural hypotension may occur, especially with high doses. 3. Nitrate preparations can act as physiological antagonists to noradrenaline, acetylcholine, histamine and other agents. 4. Dry rash and/or exfoliative dermatitis have been described rarely with isosorbide dinitrate and similar reactions might be expected occasionally. **Overdosage:** Overdosage should be treated symptomatically. The main symptom is likely to be hypotension and this may be treated by elevation of the legs to promote venous return. **Pharmaceutical Precautions** Store at room temperature, protected from moisture. **Legal Category** POM. **Package Quantities** 'Monit' tablets are supplied in bottles of 56 tablets. **Further Information** Isosorbide mononitrate is the British Approved Name for isosorbide-5-mononitrate. Beta-blocking drugs have a different pharmacological action in angina and may have a complementary effect when co-administered with 'Monit'. **Product Licence Number** 0029/0174. **Basic N.H.S. Cost** 56 tablets £4.78.



Further information is available on request to the company

'Monit' is a trademark.